TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06641739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser assisted SPPF
Description: A full-thickness flaps were elevated. In the test sites after the SPPF access will be performed, root surface debridement will be meticulously performed, followed by intra-marrow penetrations (IMPs), on the defect walls using a 0.25 mm wide half round bur, mounted on a slow-speed handpiece. Following this, low-level laser biostimulation of the defect will be effected with an 940 nm diode laser at 3 W power, with an uninitiated 0.6mm optical fiber tip. The defects will be irradiated for 20 seconds in a continuous noncontact mode and then retracted for 8 seconds. This will be repeated for 3 times so that the defects were effectively lased for about 60 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: In the second group, following the SPPF, the defect will grafted with particulated PRF, which will be overlaid with a PRF membrane, without any adjunctive defect management measures. PRF will be prepared by collecting Intra-venous blood (from the antecubital vein) in a 10-ml sterile glass tube without anticoagulant and immediately centrifuged in a centrifugation machine at 3000 rpm for 10 minutes. It will result in the separation of blood into a structured fibrin matrix in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma (platelet poor plasma) at the top. PPP will be discarded. PRF will be easily separated from the red corpuscles base using sterile tweezers and scissors.
Study: NCT06712238

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: Comparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: Comparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: Comparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: Comparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.
Study: NCT06712433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% intranasal mupirocin ointment
Description: Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate body cleanser
Description: Chlorhexidine Gluconate (CHG) Solution Antiseptic Skin Cleanser solution is a topical skin cleanser that keeps working after it is used. CHG is a strong antiseptic (liquid used to kill germs and bacteria) that lowers the risk of infection.
Study: NCT06713122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: İntervention Group- Group receiving Symptom Management Training with Mobile Application
Description: The application to be developed in the research will be both Android and IOS supported.~Monitoring the active use of the patients from the interface by the researcher and receiving individual and collective notifications in line with the profile that the patients receiving chemotherapy will create in the application will increase the usability of the application. Thus, the benefit that users receive after active use can be determined.~The content of the Let's fight the symptoms together module will be created by experts in the field and people will be able to actively use these methods while struggling with the symptoms they experience.~Patients may not always have the opportunity to reach a nurse or health professional. In symptom management with the mobile application, artificial intelligence will be trained by the researcher and integrated into the application will help patients reach the right information without wasting time.
Study: NCT06714422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: apple group
Description: Doctors will bring apples during night shift

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no apple group
Description: No apples during night shift
Study: NCT06714500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuxValve PLlus
Description: The LuX-Valve (Jenscare Biotechnology) is a radial force-independent orthotopic TTVR device. The feasibility and efficacy of this device have been reported by several studies (11-13). However, this valve was implanted through right atrial access, where a small incision of the right chest and right atrium is needed. The LuX-Valve Plus valve replacement system is the second-generation version of the LuX-Valve and can be implanted through the jugular vein.
Study: NCT06712108

Intervention type: PROCEDURE
Intervention: tranplant
Description: double unit cord blood transplnat
Study: NCT06711432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine or phenylephrine
Description: Intraoperative use of norepinephrine or phenylephrine (norepinephrine 0.01-0.1ug/kg/min, or phenylephrine 0.15-1.1 ug/kg/min). The actual infusion speed depends on reaching the target MAP(\>=80mmHg).
Study: NCT06709911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Manipulation Stretching
Description: This group received standard hand tenosynovitis stretching therapy, which focused on the flexor and extensor muscle groups of the wrist and hand for release. Muscle tension and tendon adhesions were relieved by basic stretching maneuvers, with each intervention lasting 20-30 minutes, twice a week, over a 4- to 8-week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage and Tui Na Manipulation
Description: The group received Tui Na manipulation interventions, including pointing, pressing and rolling techniques for the tendon sheath and thumb region, focusing on the stimulation of acupoints such as Hegu, Yangchi and Waiguan. The aim of Tui Na manipulation was to relieve the inflammatory reaction around the tendon sheath, promote blood circulation and improve local function. Each intervention lasts 20-30 minutes, twice a week for 4-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: This group used pressurized blood flow restriction training, in which the proximal part of the temporal joint was pressurized by a pressurized device to restrict blood flow. The training consisted of low-load wrist flexion and extension, fist clenching and unclenching, and wrist rotation. The training intensity was set at 20%-50% 1RM, and the frequency was 2 times per week for 4 to 8 weeks. Pressurization was performed before training and the pressure was set in the range of 20-50 mmHg, and the training period was supervised by a professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnetic Bead Pressure Stimulation and Tui Na Manipulation Combined Intervention
Description: This group received the combined intervention of magnetic bead pressure stimulation and Tui Na manipulation. Before treatment, the magnetic beads were applied to specific acupoints on the hand (e.g., Hegu, Ahshi, Waiguan, etc.), fixed by breathable patches, and combined with Tui Na manipulation. During Tui Na, the magnetic beads are pressed and kneaded to further enhance the stimulation effect of the acupoints. After Tui Na, the magnetic beads remain in the affected area and can be pressed and kneaded 2-3 times a day for 3 minutes each time to produce a slight sensation of soreness and distension. The aim of the massage is to relieve the inflammatory reaction around the tendon, loosen muscle tension and tendon sheath adhesions and promote blood circulation and joint mobility. The cycle of intervention is 4 to 8 weeks.
Study: NCT06706505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based art therapy
Description: MBAT combines art therapy and mindfulness to promote self-awareness and emotional well-being. It uses art to express thoughts and feelings, while cultivating mindfulness skills. MBAT addresses stress, anxiety, and emotional regulation. Grounded in research, it's an effective therapeutic approach.~The mindfulness-based art therapy sessions were designed based on the literature, drawing on the researches. By integrating art therapy techniques and mindfulness practices, the sessions were developed. Expert opinions were sought from specialists in the field to ensure the content validity of the sessions, and necessary adjustments were made accordingly. The MBAT application consists of five sessions in total. Each session has a specific theme and is designed to last 90-120 minutes.
Study: NCT06703489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphere-9 Catheter with the Affera Mapping and Ablation System
Description: Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia due to prior myocardial infarction will be enrolled and undergo ablation with the Sphere-9 Catheter with the Affera Mapping and Ablation System.
Study: NCT06711302

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RIC
Description: Remote Ischemic Conditioning is given twice a day with 60mmHg pressure.
Study: NCT05903339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 Pr-NP1 100mcg
Description: (100 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 Pr-NP1 100mcg
Description: (100 mcg)
Study: NCT06711302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning treatment instrument
Description: Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
Study: NCT06712784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Package (for both simulation and procedure sessions
Description: Treatment Package for both simulation and procedure sessions will include visit priming (contingency specifying stimuli in the form of social stories and YouTube videos) and differential reinforcement of alternative behavior (DRA).
Study: NCT06713668

Intervention type: DEVICE
Group type: OTHER
Intervention: Backup Pacing Rate Change
Description: Patients will have backup pacing programmed to A (75 bpm) and B (100 bpm), randomizing to sequence of exposure A-B or B-A

Intervention type: DEVICE
Group type: OTHER
Intervention: Backup Pacing Rate Change
Description: Patients will have backup pacing programmed to A (75 bpm) and B (100 bpm), randomizing to sequence of exposure A-B or B-A
Study: NCT06712927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg of Ipilimumab will be administered via IV every 8 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg of Ipilimumab will be administered via IV every 8 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab FDC
Description: Relatlimab 160mg + Nivo 480mg will be administered via IV every 4 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab FDC
Description: Relatlimab 160mg + Nivo 480mg will be administered via IV every 4 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur
Study: NCT06714435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Description: Intermittent hypoxia during 6 hours in daytime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Description: Intermittent hypoxia during 6 hours in daytime
Study: NCT06714513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP101
Description: QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP101
Description: QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
Study: NCT06284902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl Coated tablet
Description: Film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl Coated tablet
Description: Film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl Coated tablet
Description: Film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl Coated tablet
Description: Film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl Coated tablet
Description: Film-coated tablet.
Study: NCT06714513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP101
Description: QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP101
Description: QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP101
Description: QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP101
Description: QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP101
Description: QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP101
Description: QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% normal saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% normal saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% normal saline
Study: NCT06284902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl Coated tablet
Description: Film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl New Formulation Tablet
Description: New formulation tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl New Formulation Tablet
Description: New formulation tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl New Formulation Tablet
Description: New formulation tablet.
Study: NCT06714513

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% normal saline
Study: NCT06402331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2265
Description: PSMA ligand radiolabeled with Ac225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2265
Description: PSMA ligand radiolabeled with Ac225
Study: NCT06597513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab
Description: Induction:~Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.~Those without disease progression will advance to consolidation treatment.~Consolidation:~Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.~After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.~Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.~Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.~Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.~Maintenance:~Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision.
Study: NCT06713083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Specifically designed and structured exercise program (based on resistance/strength, designed to be executed in bed or minimal mobility). It is an adaptation from the exercise program described by Brun CR et al (Brun CR, Shoemaker JK, Bocking A, Hammond JA, Poole M, Mottola MF. Bed-rest exercise, activity restriction, and high-risk pregnancies: a feasibility study. Applied Physiology, Nutrition, and Metabolism. 2011;36(4):577-582).
Study: NCT06713564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301-IT
Description: LS301 is composed of: 1) a cyclic peptide that binds phosphorylated Annexin A2 (ANXA2) which is found on the surface of malignant cells typically located in solid tumors and in malignant lymph nodes; and 2) cypate, a near infrared (NIR) molecule conjugated to the peptide, which fluoresces when illuminated using NIR light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301-IT
Description: LS301 is composed of: 1) a cyclic peptide that binds phosphorylated Annexin A2 (ANXA2) which is found on the surface of malignant cells typically located in solid tumors and in malignant lymph nodes; and 2) cypate, a near infrared (NIR) molecule conjugated to the peptide, which fluoresces when illuminated using NIR light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301-IT
Description: LS301 is composed of: 1) a cyclic peptide that binds phosphorylated Annexin A2 (ANXA2) which is found on the surface of malignant cells typically located in solid tumors and in malignant lymph nodes; and 2) cypate, a near infrared (NIR) molecule conjugated to the peptide, which fluoresces when illuminated using NIR light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301-IT
Description: LS301 is composed of: 1) a cyclic peptide that binds phosphorylated Annexin A2 (ANXA2) which is found on the surface of malignant cells typically located in solid tumors and in malignant lymph nodes; and 2) cypate, a near infrared (NIR) molecule conjugated to the peptide, which fluoresces when illuminated using NIR light.
Study: NCT06714084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NACT)
Description: Two cycles of carbonilumab plus TP regimen neoadjuvant chemotherapy will be implemented to patients with advanced cervical cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance therapy
Description: one years of maintenance therapy with carbonilumab alone will be implemented to patients with advanced cervical cancer receiving standard concurrent chemoradiotherapy
Study: NCT06714474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Simulation Game
Description: The Virtual Simulation Game (VSG) is an interactive, scenario-based digital training tool designed to enhance venous blood sampling (VBS) skills. Participants engage with the VSG platform to complete modules that simulate real-life clinical scenarios, allowing them to refine decision-making and procedural skills in a safe, controlled environment. This intervention is used in addition to traditional training to reinforce learning through repetition and feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training
Description: Traditional training consists of theoretical instruction and hands-on practice sessions conducted in a laboratory setting. Participants observe VBS demonstrations, followed by supervised practice on peers to develop their procedural skills. This intervention represents the standard educational approach for VBS and serves as the comparator in this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Training
Description: Traditional training consists of theoretical instruction and hands-on practice sessions conducted in a laboratory setting. Participants observe VBS demonstrations, followed by supervised practice on peers to develop their procedural skills. This intervention represents the standard educational approach for VBS and serves as the comparator in this study.
Study: NCT06712966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EngageRx_SMBP
Description: Patients in the EngageRx_SMBP arm will be automatically registered in the CareSimple system and mailed a device they can use at home. They may also choose to install a smartphone application from CareSimple that will provide reminders about measuring their BP. The clinician will then manage the patient's hypertension according to the standard of care. The SMBP measurements from CareSimple will be available through EngageRx for them to use, and they will receive a weekly staff message to check EngageRx if there are new SMBP measurements for them to review. The clinician will also be able to indicate when they would like to stop using the CareSimple system.
Study: NCT06713915

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-Enhanced Mammography
Description: Only patients in the prospective cohort will undergo CEM in addition to breast ultrasound.
Study: NCT06284902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl New Formulation Tablet
Description: New formulation tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl New Formulation Tablet
Description: New formulation tablet.
Study: NCT06713733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: local infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chymotrypsin
Description: orally given